Amgen
Develops human therapeutics for various diseases.
Launch date
Employees
Market cap
€161.3b
Enterprise valuation
€209.8b (Public information from Sep 2024)
Share price
$332.92001 AMGN
Thousand Oaks California (HQ)
Corporate Venture Fund: Amgen Ventures
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 25.4b | 26.0b | 26.3b | 28.2b | 33.2b | 34.1b | 34.8b |
| % growth | 9 % | 2 % | 1 % | 7 % | 18 % | 3 % | 2 % |
| EBITDA | 9.4b | 9.4b | 8.8b | 14.8b | 18.8b | 19.2b | 19.5b |
| % EBITDA margin | 37 % | 36 % | 33 % | 53 % | 57 % | 56 % | 56 % |
| Profit | 7.3b | 5.9b | 6.6b | 6.7b | 3.5b | 6.0b | 7.1b |
| % profit margin | 29 % | 23 % | 25 % | 24 % | 11 % | 18 % | 20 % |
| EV / revenue | 6.1x | 5.8x | 6.5x | 7.4x | 6.9x | 6.6x | 6.3x |
| EV / EBITDA | 16.6x | 16.2x | 19.4x | 14.0x | 12.2x | 11.7x | 11.3x |
| R&D budget | 4.2b | 4.8b | 4.4b | 4.8b | - | - | - |
| R&D % of revenue | 17 % | 19 % | 17 % | 17 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
* | $28.5b | Post IPO Debt | |
* | N/A | Post IPO Equity | |
* | $14.4m | Post IPO Equity | |
| Total Funding | - | ||
Recent News about Amgen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Country
ACQUISITION by Amgen Dec 2022
exited
ACQUISITION by Amgen Jul 2002
ACQUISITION by Amgen Mar 2021
ACQUISITION by Amgen Aug 2022
ACQUISITION by Amgen Oct 2006
ACQUISITION by Amgen Jun 2007